Shanghai Haoyuan Chemexpress Co., Ltd.: history, ownership, mission, how it works & makes money

From its 2006 founding as a small-molecule discovery shop to a global CRO/CDMO serving over 4,000 partners by 2018, Shanghai Haoyuan Chemexpress Co., Ltd. has steadily scaled capabilities-adding a kilogram GMP plant and R&D center in 2010, building HPAPI and vitamin D derivative platforms by 2015, and launching business centers in Hong Kong and the US in 2020-today operating with roughly 3,576 employees and multiple R&D and manufacturing sites across China and Asia; publicly listed as 688131.SS with about 212.10 million shares outstanding (float ~124.54 million, insiders ~0.12%, institutions ~22.37%, shares outstanding up 0.76% year-over-year), Chemexpress generated TTM revenue of 2.71 billion CNY to Sept 30, 2025 (up 27.66% YoY), holds a market cap near 15.45 billion CNY and trades at a trailing P/E of 51.95 while monetizing its expertise through CRO/CDMO services-from custom synthesis and process R&D to APIs, intermediates and regulatory support-backed by ICH‑compliant quality systems and global business centers positioning it for continued service-led growth.

Shanghai Haoyuan Chemexpress Co., Ltd. (688131.SS): Intro

• Founded in 2006, Shanghai Haoyuan Chemexpress Co., Ltd. began as a small-molecule drug discovery and development service provider focused on medicinal chemistry and process R&D.
• 2010: Established a kilogram-scale GMP plant and an expanded R&D center to bridge discovery and commercial-scale supply.
• 2015: Built specialized platforms for highly potent active pharmaceutical ingredients (HPAPIs), vitamin D derivatives, and generic API development and manufacturing.
• 2018: Reached a service footprint of over 4,000 global partners, including pharmaceutical companies and research institutes.
• 2020: Launched business centers in Hong Kong and the United States to accelerate international business development and partnerships.
• As of December 2025: Headquartered in Shanghai with approximately 3,576 employees.

• Exploring Shanghai Haoyuan Chemexpress Co., Ltd. Investor Profile: Who's Buying and Why?

• Listed on the Shanghai Stock Exchange (ticker: 688131.SS); ownership split typically includes institutional investors, strategic shareholders, management holdings, and public float (specific percentages vary with filings and market activity).
• Operates through integrated units: R&D services, kilogram/GMP manufacturing, HPAPI and vitamin D derivative platforms, and international business centers.

• Mission: To accelerate small-molecule drug discovery and supply by providing integrated R&D and GMP manufacturing solutions, with emphasis on high-safety, high-potency chemistries.
• Strategic priorities: expand HPAPI & specialty API capacity, deepen long-term partnerships with pharmaceutical companies, and grow international revenue via local business centers.

• Discovery and process R&D: medicinal chemistry, route scouting, process optimization to enable scalable manufacture.
• GMP kilogram-scale manufacturing: support from preclinical to early commercial supply with containment and specialized equipment for HPAPIs.
• Specialty platforms: dedicated production lines and expertise for HPAPIs, vitamin D derivatives, and generics API production.
• Quality and regulatory: GMP-compliant facilities, analytical development, stability testing, and regulatory dossiers to support client submissions.
• Global business development: client management and technical support via Hong Kong and U.S. centers to facilitate cross-border projects and regulatory interactions.

• Fee-for-service R&D contracts (discovery chemistry, process development, analytical services).
• Contract manufacturing (kg-scale GMP supply) for clinical and early-commercial APIs, including premium pricing for HPAPI capabilities.
• Long-term supply agreements for generic APIs and specialty derivatives (e.g., vitamin D analogs).
• Technology transfer and scale-up service fees; milestone and success-based payments for development programs.
• Value-added services (regulatory support, stability programs, custom synthesis) that increase per-project revenue.

Shanghai Haoyuan Chemexpress Co., Ltd. (688131.SS): History

• Public listing: Ticker 688131.SS on Shanghai Stock Exchange (STAR Market).
• Shares outstanding (Dec 2025): ~212.10 million.
• Float available for public trading: ~124.54 million shares.

• Insiders: ~0.12% - limited insider alignment and concentrated public ownership.
• Institutions: ~22.37% - moderate institutional interest provides some analyst and fund coverage.
• Public float: ~124.54 million shares supports daily liquidity on the exchange.

• Provide secure, compliant and efficient logistics and distribution services for specialty chemicals and pharmaceutical intermediates.
• Reduce working capital needs for suppliers and buyers via inventory management and supply-chain financing solutions.
• Leverage bonded logistics and regulatory expertise to accelerate cross-border and domestic chemical flows.

• Core revenue streams:
  • Warehousing and bonded storage fees - long-term contracts with chemical producers and traders.
  • Distribution and logistics services - handling, packaging, and inland/port transport fees.
  • Value-added services - quality testing, repackaging, and regulatory compliance support.
  • Supply-chain finance - interest and service fees from financing inventory for suppliers/customers.
• Business model drivers:
  • High asset utilization of bonded warehouses improves margins.
  • Scale and network effects lower per-unit logistics costs as throughput increases.
  • Institutional relationships enable financing products that generate non-operating revenue.
• Key financial/capital considerations:
  • Equity base: ~212.10M shares outstanding provides owner funding and public capital access.
  • Liquidity: float of ~124.54M shares supports market trading and potential secondary financing.
  • Share growth: modest +0.76% in shares outstanding year-over-year indicates limited dilution pressure.

Shanghai Haoyuan Chemexpress Co., Ltd. (688131.SS): Ownership Structure

• Mission: To be the partner of choice for customers by providing affordable and optimized solutions in the development of new therapeutics.
• Vision: To facilitate the research and development of new therapeutics by offering quality products and services based on scientific innovation and technological optimization.
• Core values: responsibility, teamwork, professionalism, efficiency, and sustained growth; integrity and honesty in dealings with customers, employees, and investors.
• Commitment: Contributing to the healthy growth of the Chinese biomedical industry through collaborative culture and global ambition.

• R&D and product pipelines focused on enabling small-molecule and biologics discovery with scalable manufacturing capabilities.
• Customer-centric services emphasizing cost-efficient custom synthesis, analytical support, and process optimization.
• Cross-functional teams and partnerships to accelerate timelines for academic and biotech clients.

• Product sales: catalog and custom chemical reagents, building blocks, and reference compounds sold to academic, biotech, and pharma clients.
• Service revenue: contract research and manufacturing (custom synthesis, process development, scale-up) billed per project or on milestone schedules.
• Value-added technical services: analytical development, impurity profiling, and regulatory support that command premium margins.
• Strategic collaborations and licensing: select partnerships for co-development or supply agreements that include upfront, milestones, and supply revenue.

• Scaling custom synthesis capacity improves gross margins by shifting revenue mix toward higher-margin services.
• Investments in automation and analytical platforms reduce per-sample cost and shorten delivery times, improving customer retention and average revenue per client.
• Maintaining high R&D intensity supports proprietary processes that create differentiation and pricing power.

Shanghai Haoyuan Chemexpress Co., Ltd. (688131.SS): Mission and Values

• Core service areas:
  • Customized synthesis and route scouting
  • Process R&D and scale-up development
  • APIs, intermediates, and regulatory starting material manufacturing
  • Quality research and drug registration support
• Strategic objectives:
  • Deliver ICH-compliant quality systems for pharmaceutical manufacturing
  • Expand capacity for high-potency and multi-chiral molecules
  • Support global customers with localized business centers

• Platform architecture:
  • Multi-disciplinary R&D teams handling medicinal chemistry, process chemistry, analytical development, and solid-state chemistry.
  • Manufacturing teams operating GMP-compliant facilities for API and intermediate production.
  • Regulatory and quality assurance units ensuring ICH-aligned documentation, stability testing, and batch release processes.
• Service flow:
  1. Client inquiry → technical assessment and feasibility study
  2. Route design and lab-scale synthesis → analytical method development
  3. Pilot-scale process optimization → toxicity/HPAPI containment planning where applicable
  4. Commercial GMP manufacture, QC release, and dossier support for registration

• Complex multi-chiral drug technology platform
• Drug solid-state chemistry research and polymorph screening platform
• HPAPI (highly potent active pharmaceutical ingredient) development and containment platform
• Vitamin D derivative API R&D platform
• Targeted drug discovery and targeted-delivery chemistry platform

• Business centers established in:
  • Hong Kong
  • United States
  • Europe
  • Japan
  • Korea
  • India
  • Southeast Asia
• R&D and manufacturing sites include at least four major locations:
  • Anhui Ma'anshan
  • Yantai
  • Hefei
  • Chongqing

• ICH-aligned quality control and assurance systems covering method validation, stability testing, batch release, deviation management and CAPA.
• Analytical platforms supporting HPLC/UPLC, MS, chiral separations, solid-state characterization (DSC, PXRD), and residual solvents testing.
• Dedicated processes for HPAPI containment and environmental health & safety compliance at manufacturing sites.

• Revenue streams:
  • Custom synthesis and R&D services (fee-for-service, milestone payments)
  • Commercial API and intermediate sales (contract manufacturing)
  • Licensing, supply agreements, and registration-support consulting
• Value drivers:
  • Technical differentiation in multi-chiral and HPAPI chemistries
  • GMP capacity and speed-to-clinic for clients
  • Global customer access via regional business centers

• Number of major manufacturing/R&D sites: 4 (Anhui Ma'anshan, Yantai, Hefei, Chongqing)
• Number of international business centers/markets served: 7 (HK, US, Europe, Japan, Korea, India, SE Asia)
• Primary product/services categories: regulatory starting materials, APIs, intermediates, custom synthesis, registration support

Shanghai Haoyuan Chemexpress Co., Ltd. (688131.SS): How It Works

• Primary service lines: custom synthesis and novel building block supply, process R&D and scale‑up, API and intermediate production, quality research and regulatory support.
• Customer base: global biotech and pharmaceutical companies requiring discovery support, clinical supply and commercial APIs.
• Geographic footprint: R&D centers + manufacturing sites in Anhui Ma'anshan, Yantai, Hefei and Chongqing to provide integrated end‑to‑end services.

• Fee-for-service CRO work: discovery chemistry, synthesis of reference compounds, and non‑GMP/GLP early stage support billed by project milestones or hourly/flat fees.
• CDMO project fees: process development, scale‑up and technology transfer services priced per phase (lab → pilot → commercial) plus milestone payments.
• Manufacturing and supply contracts: GMP APIs, intermediates, regulatory starting materials and finished drug products supplied under long‑term supply or spot contracts, generating recurring manufacturing revenue.
• Regulatory & quality services: fees from registration support, quality testing and stability studies tied to product registrations and client filings.
• Value‑added reagents and building blocks: sale of novel building blocks and specialty intermediates with higher gross margins and repeat purchase behavior.

• Multi‑site manufacturing network (Anhui Ma'anshan, Yantai, Hefei, Chongqing) enabling flexible capacity allocation and risk mitigation across regions.
• State‑of‑the‑art quality control and QA systems aligned with ICH guidelines to support global regulatory submissions and GMP production.
• Integrated R&D centers focused on medicinal chemistry, process chemistry and analytical development to shorten timelines from concept to clinic.
• Customized manufacturing scales from gram‑scale discovery material to multi‑ton commercial API production-allowing the company to capture revenue at multiple lifecycle stages of a drug.

• Higher gross margins are typically achieved on registered API manufacturing and proprietary building blocks versus early‑stage discovery services, which are more labor‑intensive and lower margin.
• Scale and multi‑site footprint reduce per‑unit COGS for commercial APIs through larger batch sizes and CAPEX absorption over higher volumes.
• Quality and regulatory compliance (ICH, GMP) permit pricing power and access to regulated markets (EU, US, Japan), improving long‑term contract value.

• Milestone + supply agreement: upfront fee for process development, milestone payments for scale‑up, and long‑term supply priced per kg with annual price review.
• Long‑term toll manufacturing: capacity reservation with fixed and variable fee components to secure predictable utilization and revenue.
• Spot/one‑off synthesis: higher per‑unit price but lower predictability-used for novel building blocks and reference compounds.

• Expanding registered API portfolio to capture recurring commercial supply revenue.
• Deepening discovery partnerships to convert early‑stage projects into later‑stage CDMO opportunities.
• Investing in capacity and analytical/QC capabilities to serve regulated export markets and secure higher‑margin accounts.

Shanghai Haoyuan Chemexpress Co., Ltd. (688131.SS): How It Makes Money

• Primary revenue streams: custom synthesis & contract R&D, manufacturing & supply of APIs/intermediates, specialty reagents and analytical services.
• Geographic diversification: business centers in Hong Kong, USA, Europe, Japan, Korea, India, Southeast Asia - enabling higher-margin international contracts.
• R&D-driven margin expansion: in-house discovery chemistry, process optimization and scale-up capabilities shorten timelines and capture value across the project lifecycle.

• How projects are priced: milestone and time-and-material structures for R&D; capacity-based and per-kg pricing for manufacturing; premium pricing for expedited or regulated (GMP) production.
• Value capture: moving projects from discovery to commercial supply increases lifetime revenue per client through recurring manufacturing contracts and licensing where applicable.
• Investment focus: ongoing capital allocation to R&D centers and manufacturing sites to support higher-throughput, compliant production and to expand service offerings.